NasdaqGS - Nasdaq Real Time Price USD

ALX Oncology Holdings Inc. (ALXO)

10.63 -0.02 (-0.19%)
At close: May 31 at 4:00 PM EDT
10.63 0.00 (0.00%)
After hours: May 31 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
--
--
--
--
1,182.00
--
Cost of Revenue
--
--
--
--
1,075.00
4,360.00
Gross Profit
--
--
--
--
107.00
436.00
Operating Expense
175,837.00
170,278.00
127,436.00
83,555.00
43,770.00
--
Operating Income
-175,837.00
-170,278.00
-127,436.00
-83,555.00
-43,663.00
--
Net Non Operating Interest Income Expense
9,355.00
9,084.00
4,040.00
78.00
124.00
--
Other Income Expense
280.00
389.00
-22.00
-7.00
-1,960.00
--
Pretax Income
-166,202.00
-160,805.00
-123,418.00
-83,484.00
-45,499.00
--
Tax Provision
--
--
64.00
-21.00
241.00
--
Net Income Common Stockholders
-166,202.00
-160,805.00
-123,482.00
-83,463.00
-50,942.00
--
Diluted NI Available to Com Stockholders
-166,202.00
-160,805.00
-123,482.00
-83,463.00
-50,942.00
--
Basic EPS
-3.71
--
-3.03
-2.07
-2.76
-1.06
Diluted EPS
-3.71
--
-3.03
-2.07
-2.76
-1.06
Basic Average Shares
45,302.33
--
40,699.61
40,308.05
18,485.34
21,951.36
Diluted Average Shares
45,302.33
--
40,699.61
40,308.05
18,485.34
21,951.36
Total Operating Income as Reported
-175,837.00
-170,278.00
-127,436.00
-83,555.00
-43,663.00
--
Total Expenses
175,837.00
170,278.00
127,436.00
83,555.00
44,845.00
--
Net Income from Continuing & Discontinued Operation
-166,202.00
-160,805.00
-123,482.00
-83,463.00
-45,740.00
--
Normalized Income
-166,202.00
-160,805.00
-123,482.00
-83,463.00
-45,286.67
--
Interest Income
10,960.00
10,649.00
4,278.00
91.00
124.00
--
Interest Expense
1,605.00
1,565.00
238.00
13.00
811.00
--
Net Interest Income
9,355.00
9,084.00
4,040.00
78.00
124.00
--
EBIT
-164,597.00
-159,240.00
-123,180.00
-83,471.00
-43,663.00
--
EBITDA
-163,760.00
-158,404.00
-122,838.00
-83,420.00
-43,461.00
--
Reconciled Cost of Revenue
--
--
--
--
1,075.00
4,360.00
Reconciled Depreciation
837.00
836.00
342.00
51.00
202.00
--
Net Income from Continuing Operation Net Minority Interest
-166,202.00
-160,805.00
-123,482.00
-83,463.00
-45,740.00
--
Total Unusual Items Excluding Goodwill
--
--
--
--
-621.00
--
Total Unusual Items
--
--
--
--
-621.00
--
Normalized EBITDA
-163,760.00
-158,404.00
-122,838.00
-83,420.00
-42,840.00
--
Tax Rate for Calcs
--
--
0.00
0.00
0.00
--
Tax Effect of Unusual Items
--
--
--
--
-167.67
--
12/31/2019 - 7/17/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BCYC Bicycle Therapeutics plc
22.19
+1.23%
 
ANVS Annovis Bio, Inc.
6.55
+9.17%
 
BCAB BioAtla, Inc.
1.5100
-0.33%
 
IMCR Immunocore Holdings plc
48.98
+4.86%
 
REPL Replimune Group, Inc.
5.27
+3.33%
 
JANX Janux Therapeutics, Inc.
53.50
+6.13%
 
CGEM Cullinan Therapeutics, Inc.
23.50
+3.12%
 
EWTX Edgewise Therapeutics, Inc.
17.13
-2.11%
 
IMVT Immunovant, Inc.
25.39
-3.86%
 
ENTX Entera Bio Ltd.
2.2500
-2.60%